PaxMedica Receives Emergency Request For IV Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
PaxMedica Receives Emergency Request For IV Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
PaxMedica 收到非洲衛生部的靜脈注射舒拉明的緊急申請，用於治療致命的昏睡病
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations
As previously reported, PaxMedica recently executed final registration and validation batches of PAX-101 (an IV form of suramin) in preparation for a future NDA submission as an orphan designated drug
用於治療最嚴重的非洲昏睡病的藥物的緊急短缺，使受影響的國家迫切需要直接進入全球藥品市場
正如先前報道的那樣，PaxMedica 最近執行了 PAX-101（一種靜脈注射形式的舒拉明）的最終註冊和驗證批次，爲未來作爲孤兒指定藥物提交保密協議做準備
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for...
紐約塔裏敦，2024年4月16日（GLOBE NEWSWIRE）——通過IBN—...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。